Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Molecules (Basel, Switzerland)|January 28, 2026
Computational Identification of Blood-Brain Barrier-Permeant Microbiome Metabolites with Binding Affinity to Neurotransmitter Receptors in Neurodevelopmental DisordersRicardo E Buendia-Corona, María Fernanda Velasco Dey, Lisset Valencia Robles, et al.Genome Biology|April 25, 2012
High levels of RNA-editing site conservation amongst 15 laboratory mouse strainsPetr Danecek, Christoffer Nellåker, Rebecca E McIntyre, et al.Veterinary Dermatology|May 14, 2025
Literature review and authors' consensus recommendations for the medical management of perianal fistulae in dogsV Bruet, E Buendia, M C Cadiergues, et al.Breast Cancer Research and Treatment|July 24, 2021
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancerSara M Balch, Ines Vaz-Luis, Tianyu Li, et al.International Journal of Molecular Sciences|December 30, 2025
Overexpression of ITGB3 in Peripheral Blood Mononuclear Cells of Relapsing-Remitting Multiple Sclerosis PatientsGiselle Berenice Vela Sancho, Ricardo E Buendia-Corona, María Paulina Reyes-Mata, et al.Nature Communications|March 20, 2024
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trialJorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2020
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast CancerPingping Mao, Ofir Cohen, Kailey J Kowalski, et al.Cancer Discovery|May 15, 2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast CancerSeth A Wander, Ofir Cohen, Xueqian Gong, et al.Nature Medicine|January 26, 2021
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcomaLivnat Jerby-Arnon, Cyril Neftel, Marni E Shore, et al.Pageof 3